Dr. Fleshner's clinical practice is in urologic oncology with research interests in prostate and bladder cancer.
Targeting MCT4 to reduce lactic acid secretion and glycolysis for treatment of neuroendocrine prostate cancer.
Cancer Med. 2018 Jun 14;:
Fine-mapping of prostate cancer susceptibility loci in a large meta-analysis identifies candidate causal variants.
Nat Commun. 2018 Jun 11;9(1):2256
Nat Genet. 2018 Jun 11;:
Prostate Cancer Prostatic Dis. 2018 Jun 06;:
J Urol. 2018 May 11;:
Does perioperative chemotherapy improve survival in upper tract urothelial carcinoma? A population based analysis.
Oncotarget. 2018 Apr 10;9(27):18797-18810
High competing risks minimize real-world utility of adjuvant targeted therapy in renal cell carcinoma: a population-based analysis.
Oncotarget. 2018 Mar 30;9(24):16731-16743
Pathol Oncol Res. 2018 Apr 06;:
Improving patient journey and quality of care: Summary from the 2nd Bladder Cancer Canada-Canadian Urological Association-Canadian Urologic Oncology Group (BCC-CUA-CUOG) bladder cancer quality of care consensus meeting.
Can Urol Assoc J. 2018 Mar 19;:
Martin Barkin Chair, Division of Urology, Department of Surgery, University of Toronto
Professor, Department of Surgery, University of Toronto